Omnicell, Inc. (NASDAQ:OMCL) Receives Average Rating of "Moderate Buy" from Brokerages

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $44.83.

OMCL has been the topic of a number of research reports. Benchmark lowered their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen upgraded shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Piper Sandler reiterated an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Wells Fargo & Company reiterated an "overweight" rating and issued a $37.00 price objective (up from $35.00) on shares of Omnicell in a research note on Friday, May 23rd. Finally, Bank of America lifted their price objective on shares of Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd.

Omnicell Trading Down 3.9%

OMCL traded down $1.09 during trading on Thursday, reaching $26.88. 621,402 shares of the stock traded hands, compared to its average volume of 563,445. The company has a quick ratio of 1.23, a current ratio of 1.38 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.26 billion, a PE ratio of 58.44, a P/E/G ratio of 7.84 and a beta of 0.76. The stock's 50-day moving average is $29.10 and its 200 day moving average is $34.11. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.75.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The firm had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same quarter in the prior year, the business earned $0.03 earnings per share. The business's quarterly revenue was up 9.5% compared to the same quarter last year. Equities analysts anticipate that Omnicell will post 1.09 earnings per share for the current year.

Institutional Investors Weigh In On Omnicell

Several institutional investors and hedge funds have recently added to or reduced their stakes in OMCL. Principal Financial Group Inc. raised its position in shares of Omnicell by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 244,644 shares of the company's stock valued at $8,553,000 after purchasing an additional 6,288 shares during the period. Jane Street Group LLC raised its position in shares of Omnicell by 7.4% during the 4th quarter. Jane Street Group LLC now owns 54,282 shares of the company's stock valued at $2,417,000 after purchasing an additional 3,725 shares during the period. Invesco Ltd. increased its holdings in Omnicell by 2.4% in the 4th quarter. Invesco Ltd. now owns 219,453 shares of the company's stock valued at $9,770,000 after acquiring an additional 5,063 shares during the last quarter. Mariner LLC increased its holdings in Omnicell by 16.1% in the 4th quarter. Mariner LLC now owns 9,075 shares of the company's stock valued at $404,000 after acquiring an additional 1,261 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Omnicell by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company's stock valued at $247,628,000 after acquiring an additional 28,573 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.